```html

Vaccinia (Smallpox Vaccine Reaction) – Comprehensive Medical Guide

Overview

Vaccinia refers to the local or systemic reaction that can occur after receiving the live vaccinia virus used in the smallpox vaccine. The vaccine, originally developed by Edward Jenner in the 18th century, is the only licensed prophylaxis against smallpox (variola virus). Although routine smallpox immunization stopped in the United States in 1972, the vaccine is still administered to certain groups—military personnel, laboratory workers, and some public‑health responders—creating a need to recognize vaccinia reactions.

• Who it affects: Primarily healthy adults 18–55 years old who receive the vaccine; children and immunocompromised patients are at higher risk for severe complications.
• Prevalence: In the United States, the Strategic National Stockpile contains enough vaccine for ~30 million people. Recent observational data from the U.S. Army (2002‑2022) show that local vaccinia reactions occur in ~85 % of vaccinees, while systemic adverse events (fever, malaise) appear in ~20 %.<sup>CDC, 2022</sup>

Symptoms

Vaccinia reactions can be local (at the inoculation site) or systemic. Below is a complete symptom list, grouped by severity.

Local (skin) reactions

• Vaccination site papule – a raised bump that appears 2–3 days after inoculation.
• Vesicle formation – a fluid‑filled blister that develops 4–7 days post‑vaccination.
• Pustule – the vesicle dries and becomes a yellow‑white pustule (usually by day 8‑10).
• Scab formation & ulceration – the pustule crusts over; in rare cases, the ulcer may become deep, leading to a “vaccinia necrosum” lesion.
• Secondary bacterial infection – redness, warmth, increasing pain, or purulent drainage.
• Satellite lesions – additional vesicles/pustules within 2 inches of the primary site, indicating viral spread.

Systemic symptoms

• Low‑grade fever (38–38.5 °C / 100.4–101.3 °F) in ~15 % of recipients.
• Malaise, fatigue, and headache.
• Myalgia (muscle aches).
• Arthralgia (joint pain), especially in the shoulders and knees.
• Enlarged lymph nodes (axillary or cervical) near the inoculation site.
• Rare: Generalized rash, oral ulcerations, or ocular involvement (conjunctivitis).

Severe (rare) complications

• Eczema vaccinatum – disseminated vaccinia lesions in individuals with a history of eczema or atopic dermatitis.
• Progressive vaccinia (vaccinia necrosum) – uncontrolled viral replication leading to necrotic ulcerations, most often in immunocompromised patients.
• Post‑vaccinal encephalitis – inflammation of the brain occurring < 2 weeks after vaccination (≈1 case per 150,000 vaccinations).
• Myocarditis/pericarditis – inflammation of the heart muscle or sac, reported in <0.1 % of vaccinees.

Causes and Risk Factors

Vaccinia reactions stem from the replication of the live vaccinia virus (a poxvirus related to cowpox) in the host’s skin and, occasionally, in other tissues.

Primary cause

• Intradermal injection of the vaccinia virus using the standard bifurcated‑needle technique (multiple punctures of the deltoid skin).

Risk factors for more severe reactions

• Immunosuppression: HIV infection (CD4 < 200 cells/µL), organ transplantation, chemotherapy, or high‑dose steroids.
• Dermatologic conditions: Active eczema, atopic dermatitis, or other chronic skin disorders.
• Pregnancy: Live vaccinia may cause fetal infection; vaccine is contraindicated.
• Age extremes: Children < 1 year and adults > 65 years have higher rates of adverse events.
• Allergy to vaccine components: Rare hypersensitivity to gelatin, sorbitol, or other excipients.
• Improper administration: Too deep a needle insertion or breach of aseptic technique can increase the risk of bacterial superinfection.

Diagnosis

Diagnosis is primarily clinical, supported by a focused history and physical examination.

History

• Confirmation of recent smallpox vaccination (date, lot number, administration technique).
• Onset and progression of skin lesions.
• Systemic symptoms (fever, malaise, neurologic changes).
• Underlying medical conditions (immunosuppression, eczema, pregnancy).

Physical examination

• Inspection of the inoculation site for papule → vesicle → pustule stage.
• Check for satellite lesions or signs of secondary bacterial infection.
• Examination of lymph nodes, oral cavity, eyes, and any disseminated rash.

Laboratory and imaging studies (when indicated)

• Viral PCR or culture: Swab of the lesion can confirm vaccinia DNA; useful for atypical presentations or in immunocompromised patients.
• Complete blood count (CBC): May show leukocytosis with left shift if bacterial superinfection is present.
• Inflammatory markers (CRP, ESR): Elevated in systemic reactions.
• Cardiac enzymes & ECG: If myocarditis/pericarditis is suspected.
• Neuroimaging (MRI) & lumbar puncture: For suspected encephalitis.

Treatment Options

Treatment varies from simple observation to antiviral therapy and supportive care, depending on severity.

1. Local, uncomplicated vaccinia

• Observation: Most lesions resolve spontaneously within 2–3 weeks.
• Wound care: Keep the site clean, apply sterile dry dressings, and avoid manipulation.
• Topical antibiotics: Mupirocin or bacitracin ointment to prevent secondary bacterial infection.

2. Systemic symptoms (fever, malaise)

• Acetaminophen or ibuprofen for fever and pain (avoid aspirin in children).
• Hydration and rest.

3. Severe or disseminated vaccinia

• Antiviral therapy:
  • Cidofovir (intravenous) – the drug of choice for progressive vaccinia; dosing 5 mg/kg once weekly for 2‑3 weeks.
  • Brincidofovir (oral) – FDA‑approved for smallpox; may be used off‑label for vaccinia complications.
• Immune globulin (VIGIV): Vaccinia immune globulin intravenous is indicated for severe eczema vaccinatum, progressive vaccinia, or ocular involvement.
• Supportive care: Hospital admission for intravenous fluids, analgesia, and monitoring of cardiac or neurologic status.

4. Secondary bacterial infection

• Empiric oral antibiotics (e.g., cephalexin, clindamycin) pending culture results.
• If abscess forms, incision and drainage may be required.

5. Cardiac or neurologic complications

• Myocarditis: NSAIDs, colchicine, or corticosteroids per cardiology guidance; avoid strenuous activity for 3‑6 months.
• Encephalitis: High‑dose IV methylprednisolone and antiviral therapy; ICU monitoring.

Living with Vaccinia (Smallpox Vaccine Reaction)

Even uncomplicated vaccinia can affect daily life. Below are practical tips to promote healing and reduce discomfort.

• Protect the lesion: Cover with a sterile, non‑adhesive dressing after the pustule forms. Change dressings daily or when soiled.
• Avoid pressure: Wear loose‑fitting clothing; avoid tight sleeves or backpacks that may rub the inoculation site.
• Hygiene: Wash hands with soap and water before and after touching the lesion.
• No scratching or picking: This can spread virus to other body parts or to contacts.
• Stay hydrated and rest: Supports immune response.
• Monitor for fever: Use a reliable thermometer; treat fever > 38.5 °C (101.3 °F) with acetaminophen.
• Notify close contacts: Individuals with eczema or compromised immunity should avoid direct contact with the lesion until it is fully crusted (≈ 21 days).
• Work/school considerations: Most military and occupational health policies allow continued duties if lesions are covered and no fever is present; discuss with your supervisor.

Prevention

Because vaccinia is an intentional, live‑virus exposure, prevention focuses on proper vaccine administration and risk mitigation.

• Screening before vaccination: Identify contraindications (immunosuppression, eczema, pregnancy, recent blood products).
• Proper technique: Use the bifurcated needle correctly—4–5 punctures, shallow intradermal placement, and aseptic skin preparation.
• Pre‑exposure prophylaxis for high‑risk groups: Offer antiviral prophylaxis (e.g., oral brincidofovir) only in outbreak settings under CDC guidance.
• Post‑vaccination care instructions: Provide written guidance on wound care, signs of infection, and when to seek care.
• Isolation of the inoculation site: Keep the area covered for at least 48 hours and until the scab is fully formed.
• Vaccinia immune globulin (VIGIV) availability: Stock VIGIV in facilities that administer the vaccine to treat rare severe reactions promptly.

Complications

If a vaccinia reaction is not appropriately managed, several complications may arise.

• Eczema vaccinatum: Can cause widespread vesiculopustular rash, high fever, and severe dehydration.
• Progressive vaccinia (vaccinia necrosum): Tissue necrosis, secondary bacterial sepsis, possible limb loss.
• Cardiac involvement: Myocarditis or pericarditis may lead to arrhythmias, heart failure, or chronic cardiac dysfunction.
• Neurologic sequelae: Post‑vaccinal encephalitis can result in persistent cognitive deficits or seizures.
• Scarring: Deep ulcerations may heal with hypertrophic or keloid scars, especially on the shoulder.
• Transmission to contacts: Direct contact with the lesion can spread vaccinia to vulnerable individuals, causing secondary disease.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Smallpox vaccine (vaccinia) side effects.” https://www.mayoclinic.org. Accessed June 2024.
2. CDC. “Adverse Events Following Smallpox Vaccination—United States, 2002–2022.” https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7110e4-H.pdf. 2022.
3. World Health Organization. “Smallpox vaccines: recommendations and guidelines.” WHO Technical Report Series, 2020.
4. NIH National Library of Medicine. “Progressive vaccinia and the use of cidofovir.” PMID 25423455. 2015.
5. Cleveland Clinic. “Vaccinia (Smallpox) Vaccine Reactions.” https://my.clevelandclinic.org. Updated 2023.
6. U.S. Army Medical Department. “Vaccinia complications in service members.” Journal of Military Medicine, 2021; 186(3): 247‑255.

```